Publication date: Mar 02, 2019
Efficacy and safety profiles of alemtuzumab for relapsing-remitting multiple sclerosis (RRMS) mainly come from Western countries and have not been reported in Asian populations. The aim of this study was to report the efficacy and safety of alemtuzumab for RRMS patients in a Korean population.
We retrospectively reviewed RRMS patients treated with alemtuzumab. Study outcomes included annualized relapse rate (ARR), expanded disability status scale (EDSS) score, 6-month confirmed disability worsening (CDW), confirmed disability improvement (CDI), MRI lesion activity (new/enlarging T2 hyperintense and gadolinium-enhancing T1 lesions), no evidence of disease activity (NEDA), and adverse events.
Nineteen patients were identified and mean follow-up was 1.5 years after alemtuzumab initiation. Mean ARR fell from 1.20 pre-treatment to 0.30 post-treatment (p
Kim, H., Lee, E.J., Kim, S.K., Kim, K.K., and Lim, Y.M. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients. 17510. 2019 Mult Scler Relat Disord (30):
|disease||DOID||relapsing-remitting multiple sclerosis|
|disease||MESH||relapsing-remitting multiple sclerosis|